[go: up one dir, main page]

UA85931U - Method for treating serous and purulent meningitis - Google Patents

Method for treating serous and purulent meningitis

Info

Publication number
UA85931U
UA85931U UAU201305943U UAU201305943U UA85931U UA 85931 U UA85931 U UA 85931U UA U201305943 U UAU201305943 U UA U201305943U UA U201305943 U UAU201305943 U UA U201305943U UA 85931 U UA85931 U UA 85931U
Authority
UA
Ukraine
Prior art keywords
purulent meningitis
serous
treating
treating serous
day
Prior art date
Application number
UAU201305943U
Other languages
Russian (ru)
Ukrainian (uk)
Inventor
Денис Анатолійович Задирака
Олена В'ячеславівна Рябоконь
Original Assignee
Запорожский Государственный Медицинский Университет
Задирака Денис Анатольевич
Рябоконь Елена Вячеславовна
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Запорожский Государственный Медицинский Университет, Задирака Денис Анатольевич, Рябоконь Елена Вячеславовна filed Critical Запорожский Государственный Медицинский Университет
Priority to UAU201305943U priority Critical patent/UA85931U/en
Publication of UA85931U publication Critical patent/UA85931U/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The method for treating the serous and purulent meningitis provides for the basic therapy and antioxidant agent Mebicar at a dose of 500 mg twice a day starting from the 7th day of the disease for 14-21 days.
UAU201305943U 2013-05-13 2013-05-13 Method for treating serous and purulent meningitis UA85931U (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
UAU201305943U UA85931U (en) 2013-05-13 2013-05-13 Method for treating serous and purulent meningitis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
UAU201305943U UA85931U (en) 2013-05-13 2013-05-13 Method for treating serous and purulent meningitis

Publications (1)

Publication Number Publication Date
UA85931U true UA85931U (en) 2013-12-10

Family

ID=52285504

Family Applications (1)

Application Number Title Priority Date Filing Date
UAU201305943U UA85931U (en) 2013-05-13 2013-05-13 Method for treating serous and purulent meningitis

Country Status (1)

Country Link
UA (1) UA85931U (en)

Similar Documents

Publication Publication Date Title
PH12015502161A1 (en) Therapeutic compounds and compositions
NZ709635A (en) Bcl-2bcl-xl inhibitors and therapeutic methods using the same
MX2020011772A (en) Combination therapy involving antibodies against claudin 18.2 for treatment of cancer.
SG10201906471PA (en) Treatment of cancer with anti-lap monoclonal antibodies
MY198613A (en) Nitrobenzyl derivatives of anti-cancer agents
SG10201811841UA (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
MX356368B (en) Prodrugs of fumarates and their use in treating various deseases.
MX2020009780A (en) Autotaxin inhibitor compounds.
MX382162B (en) Pharmaceutical combinations for treating cancer
MX2017004618A (en) Heparan sulfate biosynthesis inhibitors for the treatment of diseases.
PH12016500270A1 (en) Combination of a mek inhibitor and an erk inhibitor for use in treatment of hyperproliferative diseases
PH12017500493A1 (en) Combination therapy
MX2015010829A (en) Therapeutic compounds and uses thereof.
WO2019173795A3 (en) Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease
PH12016502352A1 (en) Pharmaceutical composition
TW201613578A (en) Pharmaceutical combinations
MX2016009663A (en) Icariin derivatives.
MX2020001727A (en) Combination therapy.
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
IN2013MU03118A (en)
EA201990413A1 (en) METHOD OF TREATING HEPATIC ENCEPHALOPATHY
MX2021014120A (en) Treatment of androgen deprivation therapy associated symptoms.
UA85931U (en) Method for treating serous and purulent meningitis
NZ750581A (en) Compositions and methods for treating neurodegenerative diseases and cardiomyopathy
GEP20197007B (en) Therapeutic agent for frontal lobe dysfunction